344 related articles for article (PubMed ID: 2410106)
1. Immunological properties of HTLV-III antigens recognized by sera of patients with AIDS and AIDS-related complex and of asymptomatic carriers of HTLV-III infection.
Sarngadharan MG; diMarzo Veronese F; Lee S; Gallo RC
Cancer Res; 1985 Sep; 45(9 Suppl):4574s-4577s. PubMed ID: 2410106
[TBL] [Abstract][Full Text] [Related]
2. Unique pattern of HTLV-III (AIDS-related) antigen recognition by sera from African children in Uganda (1972).
Saxinger C; Levine PH; Dean A; Lange-Wantzin G; Gallo R
Cancer Res; 1985 Sep; 45(9 Suppl):4624s-4626s. PubMed ID: 2990697
[TBL] [Abstract][Full Text] [Related]
3. HTLV-III: the etiologic agent of AIDS.
Sarngadharan MG; DeVico AL; Bruch L; Schüpbach J; Gallo RC
Princess Takamatsu Symp; 1984; 15():301-8. PubMed ID: 6100648
[TBL] [Abstract][Full Text] [Related]
4. Retroviruses associated with leukemia and ablative syndromes in animals and in human beings.
Essex M; McLane MF; Kanki P; Allan J; Kitchen L; Lee TH
Cancer Res; 1985 Sep; 45(9 Suppl):4534s-4538s. PubMed ID: 2990682
[TBL] [Abstract][Full Text] [Related]
5. Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III).
Fischinger PJ; Robey WG; Koprowski H; Gallo RC; Bolognesi DP
Cancer Res; 1985 Sep; 45(9 Suppl):4694s-4699s. PubMed ID: 2410115
[TBL] [Abstract][Full Text] [Related]
6. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
[TBL] [Abstract][Full Text] [Related]
7. Human T-cell lymphotropic virus type III: immunologic characterization and primary structure analysis of the major internal protein, p24.
Casey JM; Kim Y; Andersen PR; Watson KF; Fox JL; Devare SG
J Virol; 1985 Aug; 55(2):417-23. PubMed ID: 2410630
[TBL] [Abstract][Full Text] [Related]
8. HTLV and immunosuppression.
Essex M; Kanki P; Allan J; Barin F; McLane MF; Lee TH; Kitchen L; Homma T; Malone G; Yokota T
Princess Takamatsu Symp; 1984; 15():309-18. PubMed ID: 6100649
[TBL] [Abstract][Full Text] [Related]
9. Clinical and immunological findings in HTLV-III infection.
Krohn KJ; Antonen J; Valle SL; Kazakevicius R; Saxinger C; Gallo RC; Ranki A
Cancer Res; 1985 Sep; 45(9 Suppl):4612s-4615s. PubMed ID: 2990694
[TBL] [Abstract][Full Text] [Related]
10. Immunological properties of the Gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III).
Sarngadharan MG; Bruch L; Popovic M; Gallo RC
Proc Natl Acad Sci U S A; 1985 May; 82(10):3481-4. PubMed ID: 2582414
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of cytotoxic T lymphocyte responses to influenza and antibodies to human T lymphotropic virus-III in homosexual men. Selective loss of an influenza-specific, human leukocyte antigen-restricted cytotoxic T lymphocyte response in human T lymphotropic virus-III positive individuals with symptoms of acquired immunodeficiency syndrome and in a patient with acquired immunodeficiency syndrome.
Shearer GM; Salahuddin SZ; Markham PD; Joseph LJ; Payne SM; Kriebel P; Bernstein DC; Biddison WE; Sarngadharan MG; Gallo RC
J Clin Invest; 1985 Oct; 76(4):1699-704. PubMed ID: 2997287
[TBL] [Abstract][Full Text] [Related]
12. Expression of HTLV-I in serum of HTLV-I-related subjects and the early detection of overt ATL in HTLV-I carriers.
Ishibashi K; Hanada S; Hashimoto S
J Immunol; 1987 Sep; 139(5):1509-13. PubMed ID: 2442248
[TBL] [Abstract][Full Text] [Related]
13. [Immunological changes in HTLV-III infections and AIDS].
Krohn K; Antonen J
Duodecim; 1986; 102(7):413-22. PubMed ID: 2424708
[No Abstract] [Full Text] [Related]
14. Human T-cell lymphotropic virus type III associated disorders. The spectrum in the heterosexual population.
Gill PS; Levine AM; Meyer PR; Aguilar SL; Rarick M; Parker JW; Rasheed S
Arch Intern Med; 1986 Aug; 146(8):1501-4. PubMed ID: 3015064
[TBL] [Abstract][Full Text] [Related]
15. Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS.
Schüpbach J; Haller O; Vogt M; Lüthy R; Joller H; Oelz O; Popovic M; Sarngadharan MG; Gallo RC
N Engl J Med; 1985 Jan; 312(5):265-70. PubMed ID: 2981407
[TBL] [Abstract][Full Text] [Related]
16. [Prevalence of antibodies against HTLV-III in various regions in Switzerland].
Schüpbach J; Vogt M; Bhushan R; Lüthy R; Haller O; Joller H; Ferber T; Büchner S; Schuppli R; Schädelin J
Schweiz Med Wochenschr; 1985 Jul; 115(30):1048-54. PubMed ID: 2994208
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies reactive with human T cell lymphotropic virusI (HTLVI) p19 internal core protein: cross-reactivity with normal tissues and differential reactivity with HTLV types I and II.
Palker TJ; Scearce RM; Ho W; Copeland TD; Oroszlan S; Popovic M; Haynes BF
J Immunol; 1985 Jul; 135(1):247-54. PubMed ID: 2987346
[TBL] [Abstract][Full Text] [Related]
18. Human retroviral env and gag polypeptides: serologic assays to measure infection.
Kanner SB; Cheng-Mayer C; Geffin RB; Parks WP; Beltz GA; Arthur LO; Samuel KP; Papas TS
J Immunol; 1986 Jul; 137(2):674-8. PubMed ID: 3014000
[TBL] [Abstract][Full Text] [Related]
19. Sera of adult T-cell leukemia patients and carriers of human T-cell leukemia virus type I in Japan do not cross-react with antigens of lymphadenopathy virus.
Katamine S; Sugiyama H; Moriuchi R; Miyamoto T; Hino S
Jpn J Cancer Res; 1985 Apr; 76(4):245-8. PubMed ID: 2989058
[TBL] [Abstract][Full Text] [Related]
20. [Properties and transmission of the AIDS virus].
Laufs R
Hautarzt; 1986 May; 37(5):245-9. PubMed ID: 3015839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
